CDMO Piramal Pharma Solutions (PPS), based in Mumbai, India, agreed to acquire a 100% stake in Hemmo Pharmaceuticals in a deal that will add peptide API development and manufacturing capabilities to PPS’ operations.
Hemmo, which is one of the few pure-play synthetic peptide API manufacturers in the global marketplace, according to PPS, is one of India’s largest manufacturers of synthetic peptides with a history of more than thirty-eight years in supplying peptide products and custom peptide synthesis.
Hemmo reportedly has R&D capabilities and a world-class GMP manufacturing facility that has been inspected and deemed compliant by the U.S., EU, and Asian regulatory agencies. The company has strong expertise in both solution phase and solid phase synthesis of peptides, notes Nandini Piramal, chairperson, PPS.
“Hemmo has demonstrated excellence and a great quality track record with a differentiated and hard to replicate capability,” adds Piramal.
The acquisition is expected to add more than two-hundred and fifty employees to PPS, including several PhD scientists and a quality team of more than sixty.
By Piramal Healthcare (UK)